Last updated: 2026-09-16 09:45:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
OKYO Pharma Limited (OKYO) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1,35, with a market capitalisation of $73,47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,32 to $3,20. This page covers its latest market performance, valuation, price trends and company information.
$73,47M | |
$1,35 | |
$7,00 | |
$0,81 | |
$1,34 | |
1,00 | |
106,01K | |
-- | |
$3,20 | |
$1,32 | |
-- | |
-- |
OKYO Pharma Limited (OKYO) is trading at $1,35 in pre-market trading as of 2026-09-16 08:01:00, up 0,37% ($0,00) from the previous close of $1,34
Pre-market trading shows how investors are pricing OKYO before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, OKYO Pharma Limited (OKYO) moved from $1,57 to $1,35, representing a decline of 14,33% ($0,23).
The stock traded between $1,32 and $1,60 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 115,13 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 1,3%
OKYO is currently trading at $1,35, placing it 1,3% of the way from its 52-week low of $1,32 to its 52-week high of $3,20. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of OKYO Pharma Limited (OKYO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.